Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 Blockade

INTRODUCTION

Meningiomas are the most common primary tumor of the CNS; there are approximately 28,000 new diagnoses annually in the United States. Currently, there are no approved systemic therapies for meningiomas that recur after local treatment: chemotherapy and hormonal agents have demonstrated minimal benefit in numerous clinical trials.

Meningiomas comprise a heterogeneous group of neoplasms driven by mutations in a wide array of tumor suppressor genes and oncogenes. Characterization of these mutations has revealed opportunities for rational therapy. For example, a durable therapeutic response has been reported for a metastatic AKT1 E17K–mutant meningioma treated with a pan-AKT inhibitor.

Studies also suggest the potential for treating meningioma with immune checkpoint modulators: programmed death ligand 1 (PD-L1) is expressed in a subset of meningiomas, and the tumor microenvironment is immunosuppressive. Higher-grade meningiomas also harbor mutations predicted to generate neoantigens, which may foster susceptibility to immunotherapies.

On the basis of these data, we initiated a phase II study of nivolumab, a humanized IgG4–blocking monoclonal antibody, in patients with higher-grade meningiomas that recurred after surgery and radiotherapy (ClinicalTrials.gov identifier: NCT02648997). We report here a patient with an atypical meningioma that was not controlled by repeated surgery and radiation but that was highly responsive to nivolumab.

CASE REPORT

A 50-year-old woman with progressive headaches underwent a gross total resection (surgery 1) of a gadolinium-enhancing right frontal convexity atypical meningioma (WHO grade 2; Fig 1A). The tumor recurred 10 months later and was treated with stereotactic radiosurgery (SRS; SRS 1, 25 Gy/five fractions). Recurrent atypical meningioma was debulked 17 months (surgery 2) and 21 months (surgery 3) after the original diagnosis. The patient then underwent conventional radiotherapy (RT; conformal RT, 54 Gy/27 fractions). Three months later, she again underwent SRS (SRS 2, 14 Gy/one fraction) because of tumor spread to the sphenoid ridge and infratemporal fossa. Additional debulking surgeries for recurrent atypical meningioma were performed at 46 months (surgery 4) and 49 months (surgery 5). She then received bevacizumab for 11 months, mifepristone for 7 months, and temozolomide for 4 months. Each therapy was discontinued after disease progression occurred. A sixth debulking surgery (surgery 6) at 70 months confirmed recurrent atypical meningioma.

Five weeks later, the patient enrolled in our phase II nivolumab clinical trial. At that time, 75 months after the original diagnosis, painful subcutaneous masses overlaid the right convexity. The patient required oxycodone for scalp pain and dexamethasone (4 mg/day) for worsening headache. Pretreatment magnetic resonance imaging (MRI) showed an enlarging-enhancing right sphenoid wing mass, plaque-like dural enhancement over the right convexity, tumor erosion through the occipital skull, and an...
increased fluid-attenuated inversion recovery (FLAIR) signal abnormality that involved the right hemisphere (Fig 1B).

The patient received nivolumab 3 mg/kg on days 1 (dose 1) and 15 (dose 2) of cycle 1 without incident, but her headaches and scalp pain worsened. The scalp masses were notably larger, erythematous, and more tender by day 28. Brain MRI showed significantly enlarged dural-based enhancing lesions, increased T2 and FLAIR signal abnormalities, and enlarged scalp masses (Fig 1C). Her physical examination and MRI appeared consistent with progressive disease, and we withheld additional nivolumab. She underwent palliative debulking surgery 3 weeks later (surgery 7). Immediately before surgery, her scalp masses were modestly smaller and less tender. Postoperative MRI showed a subtotal resection (Fig 1D).

MATERIALS AND METHODS

Patient Consent

Our patient provided informed consent for our institutional review board–approved study and consented to this publication. We obtained all permissions required by law and by the Dana-Farber Cancer Institute (DFCI)/Harvard Cancer Center to allow the publication of images from the patient.

Immunohistochemistry

We used immunohistochemistry (IHC) to evaluate protein expression using Envision Plus detection (Dako, Carpinteria, CA; Data Supplement) and published protocols.30,31

Multiplexed Immunofluorescence

The protocol for tissue-based multiplexed cyclic immunofluorescence (t-CyCIF) of conventionally prepared formalin-fixed, paraffin-embedded specimens and image analysis are described elsewhere.32,33 Antibodies are listed in the Data Supplement.

Oncopanel Sequencing

We used targeted next-generation exome sequencing (Oncopanel version 3; DFCI/Brigham and Women’s Hospital [BWH]) to detect mutations and copy number variations in 447 cancer genes.
**Fig 2.** Histologic, immunohistochemical, and tissue-based multiplexed cyclic immunofluorescence (t-CyCIF) characterization of meningioma resection samples. Representative images of hematoxylin and eosin–stained section of meningioma resection (A) before treatment with nivolumab (surgery 6/sample 6; S6) and (C) after two doses of nivolumab (surgery 7/sample 7; S7). Representative images of immunohistochemistry for meningioma marker SSTR2a on resections (B) before treatment with nivolumab (surgery 6/sample 6; S6) and (D) after two nivolumab doses (surgery 7/sample 7; S7). The inset in (A) shows a mitotic figure and cells with prominent nucleoli; an elevated mitotic index of more than four mitoses per 10 high-powered fields was used for grading. (E) A representative field of view of t-CyCIF imaging data of 11 biomarkers (ionized calcium-binding adapter molecule 1 [IBA], CD45RB, CD14, CD3, marker of proliferation Ki-67 [Ki-67], CD20, CD4, CD8A, programmed cell death 1 [PD-1], forkhead box P3 [FOXP3], programmed death ligand 1 [PD-L1]) generated from a single section of pretreatment meningioma (surgery 6/sample 6) and (F) from a single section of the post-treatment meningioma (surgery 7/sample 7). Comparison of the images in (E) and (F) showed a marked increase in macrophages; T lymphocytes (CD3+), including CD4+ T cells and CD8A+ T cells; and B lymphocytes (CD20+) after nivolumab treatment. The majority of T cells after treatment were CD8A+. The antibodies used for this characterization and a detailed analysis of the absolute number, relative number and density of various immune subtypes are provided in Table 1 and the Data Supplement. (G) Bar graph of the percentage of immune cell subtypes relative to all cells (immune and nonimmune) before (red bars) and after (blue bars) nivolumab treatment. (H) Bar graph of cell density before (red bars) and after (blue bars) nivolumab treatment. The analysis was performed on 10 representative views (tiles) from the t-CyCIF data collected from samples 6 and 7. $t$ test statistical analysis was performed. *, $P < .01$, †, $P < .001$, ‡, $P < .0001$. The bar graphs represent the most pertinent data derived from the immune profile of the pre-nivolumab (sample 6) and post-nivolumab (sample 7)–treated meningioma samples using t-CyCIF. Detailed data are listed in Table 1 and the Data Supplement.
We processed and annotated data as previously described.\textsuperscript{9,34,35} We calculated tumor mutational burden (TMB) by determining the number of nonsynonymous mutations per megabase (Mb) of exonic sequence data across sequenced genes.\textsuperscript{35,36}

RESULTS

Histopathologic examination of the tissue resected 5 weeks before nivolumab treatment (sample 6) revealed a highly proliferative atypical meningioma (Fig 2A). In contrast, tissue resected 3 weeks after nivolumab dose 2 (sample 7) had dense fibrosis with extensive immune cell infiltration and necrosis (Fig 2C). Tumor cells were absent in the hematoxylin and eosin–stained slides, but IHC with a marker of meningioma, SSTR2a\textsuperscript{30} (Figs 2B and 2D), revealed one small cluster (approximately 1,000 cells/µm\textsuperscript{2}) of possible residual tumor cells (which represented < 0.0001\% of resected tissue; image and data not shown).

To characterize the effects of nivolumab, we profiled the tumor and its microenvironment using t-CyCIF, a method for highly multiplexed immunofluorescence imaging of formalin-fixed, paraffin-embedded specimens.\textsuperscript{32} We imaged 11 markers (Data Supplement) on pre- and post-treatment samples to measure changes in immune cell types and the relative density of the immune infiltrate (Table 1; Figs 2E-2H; Appendix Fig A1; Data Supplement). We have previously shown that PD-L1 is overexpressed in tumor cells of some higher-grade meningiomas,\textsuperscript{22} but, in this pretreatment specimen (sample 6), we found PD-L1 restricted to immune cells. Post-treatment (in sample 7), we observed a marked increase in IBA1+/CD14+ macrophages, CD4+ and CD8+ T cells, CD20+ B cells, and FOXP3+ regulatory T cells (T\textsubscript{reg} cells; Table 1; Figs 2E-2H; Appendix Fig A1). The fraction of CD8+ T cells increased from 7% to 73% (Table 1) and CD8+ T-cell density increased from 0.5 to 304 cells/mm\textsuperscript{2}; the CD8+ T cell-to–T\textsubscript{reg} ratio increased 20-fold (from 5.8 to 115; Figs 2G-2H; Data Supplement). These data are consistent with a highly active antitumor immune response after treatment.

We used targeted-exome sequencing to characterize genomic aberrations in specimens from the original resection (sample 1); the resection before treatment with bevacizumab (sample 4); and the resection before treatment with nivolumab (sample 6; Fig 1A; Data Supplement). This analysis revealed a significantly elevated TMB of 20.5, 26.6, and 38.0 mutations/Mb in the samples, respectively (Data Supplement).\textsuperscript{37} These levels were greater than those of 228 other meningiomas sequenced as part of the BWH/DFCI profile initiative.\textsuperscript{35} Copy number variation in the three samples was characteristic of higher-grade aggressive meningioma\textsuperscript{38-41} (Fig 3A; Data Supplement). Notably, homozygous deletion of exons 2 to 5 of the DNA mismatch repair (MMR) gene MSH2 was present in all three samples (Figs 3A-3B) but was absent in a peripheral-blood specimen.

IHC showed that tumor cells were negative for the MSH2 protein and its heterodimeric partner, MSH6, but that expression of MLH1 and PMS2 protein was retained (Figs 3C-3F). Loss of MSH2/MSH6 in sample 1 demonstrated that MSH2 had been inactivated before any therapy and independent of temozolomide exposure, a known driver of acquired MMR deficiency in gliomas.\textsuperscript{42,43} Thus, the tumor was MMR deficient at the original diagnosis, and there was a progressive increase in TMB (Data Supplement).

The patient resumed nivolumab after surgery 7 and continued biweekly therapy for more than 2 years. MRI scans have shown gradual and continued regression of enhancing lesions and associated T2/FLAIR signal abnormalities (Fig 1E). Scalp lesions have disappeared, and narcotics and dexamethasone are no longer required for pain control and cerebral edema.

Given the dramatic response of this MSH2-deficient tumor to nivolumab, we investigated the prevalence of elevated TMB and MMR deficiency in meningioma (Fig 3G; Data Supplement). We used sequencing data from the BWH/DFCI profile initiative (n = 228 patient cases)\textsuperscript{35} or BWH/DFCI patient cases screened only by MMR-protein IHC (n = 237 patient cases)\textsuperscript{22,44} to study specimens from 465 patients (n = 288 with grade 1, n = 132 with grade 2, and n = 45 with grade 3 disease). Among the 228 sequenced specimens, the cohort mean TMB was 4.2 mutations/Mb (grade 1, 4.0; grade 2, 4.4; grade 3, 6.5; Data Supplement). Seven of the 228 specimens had TMBs of 10 or more mutations/Mb, a commonly used threshold for hypermutation\textsuperscript{36}; one of these meningiomas (TMB, 18 mutations/Mb) had a truncating mutation in the DNA MMR
regulator \textit{SETD2} as well as a splice site mutation in \textit{MSH2} of unclear functional significance. We discovered one occurrence with MMR protein loss discovered by IHC (one of 237 occurrences), and sequencing confirmed biallelic inactivation of \textit{MSH6} and a TMB of 10 mutations/Mb (Table 2; Fig 3G; Data Supplement). Among the sequenced meningiomas, elevated TMB was significantly positively associated with anaplastic histology, Ki-67 proliferative index, and chromosomal instability\textsuperscript{38} but not with prior radiotherapy, radiation induced meningioma, or recurrent tumor (Data Supplement).

In a second cohort of 615 sequenced meningiomas (Foundation Medicine cohort), 14 tumors had a TMB of more than 10 mutations/Mb. Among these 14 specimens, two grade 3 meningiomas had inactivating mutations in \textit{MSH2} and \textit{MSH6}; one grade 2 meningioma had a substitution in the DNA polymerase domain of the \textit{POLE} subunit of DNA polymerase epsilon, and another grade 3 meningioma had a truncating mutation in \textit{SETD2} (Table 2; Fig 3G; Data Supplement). Thus, across two cohorts of sequenced meningioma samples (n = 843), 21 (2.5\%) had high TMBs.\textsuperscript{36} Three of 1,080 meningiomas screened by sequencing or IHC (0.3\%) had detectable inactivating mutations in \textit{MSH2} or \textit{MSH6}. The number of notable tumors increased to six (0.6\%) when MMR-related genes (eg, \textit{SETD2}, \textit{POLE}) were considered.

**DISCUSSION**

In our patient with an \textit{MSH2}-deficient meningioma, nivolumab treatment generated a robust anticancer immune response, as evidenced by dramatically increased infiltrating CD8\textsuperscript{+} T cells and a durable therapeutic response. Notably,  

<table>
<thead>
<tr>
<th>Ratio</th>
<th>Pretreatment Total Cell No. (% of total cells)</th>
<th>Post-Treatment Total Cell No. (% of total cells)</th>
<th>Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cells</td>
<td>160,967 (100)</td>
<td>128,307 (100)</td>
<td>47.56</td>
</tr>
<tr>
<td>CD45RB+ (lymphocytes)</td>
<td>1,743 (1.08)</td>
<td>65,896 (51.36)</td>
<td>47.56</td>
</tr>
<tr>
<td>IBA1+/CD14+ (macrophages)</td>
<td>29,614 (18.4)</td>
<td>69,378(54.07)</td>
<td>2.94</td>
</tr>
<tr>
<td>CD45RB+ or IBA1+ or CD14+ (immune cells)</td>
<td>62,970 (39.12)</td>
<td>106,483 (82.99)</td>
<td>2.12</td>
</tr>
<tr>
<td>CD45RB−/IBA1−/CD14− (tumor cells, fibroblast)</td>
<td>97,997 (60.88)</td>
<td>21,823 (17.01)</td>
<td>0.28</td>
</tr>
<tr>
<td>CD45RB+/CD3+ (T cells)</td>
<td>513 (0.32)</td>
<td>42,273 (32.95)</td>
<td>102.97</td>
</tr>
<tr>
<td>CD45RB+/CD20+ (B cells)</td>
<td>43 (0.027)</td>
<td>3,307 (2.58)</td>
<td>95.56</td>
</tr>
<tr>
<td>CD45RB+/CD3+/CD4+ (CD4+ T cells)</td>
<td>27 (0.017)</td>
<td>8,457 (6.59)</td>
<td>387.65</td>
</tr>
<tr>
<td>CD45RB+/CD3+/CD8A+ (CD8A+ T cells)</td>
<td>35 (0.022)</td>
<td>30,906 (24.09)</td>
<td>1,095.00</td>
</tr>
<tr>
<td>CD45RB+/CD3+/CD4−/CD8A−</td>
<td>452 (0.28)</td>
<td>6,665 (5.19)</td>
<td>18.54</td>
</tr>
<tr>
<td>CD45RB+/CD3+/PD-1+</td>
<td>13 (0.0081)</td>
<td>79 (0.062)</td>
<td>7.65</td>
</tr>
<tr>
<td>CD45RB+/PD-L1+</td>
<td>2 (0.0012)</td>
<td>100 (0.078)</td>
<td>65.00</td>
</tr>
<tr>
<td>IBA1+/CD14+/PD-L1+</td>
<td>5 (0.0031)</td>
<td>59 (0.046)</td>
<td>13.43</td>
</tr>
<tr>
<td>CD45RB+/PD-1+/PD-L1+</td>
<td>0 (0)</td>
<td>25 (0.019)</td>
<td>102.97</td>
</tr>
<tr>
<td>CD45RB+/CD3+/CD4+/FOXP3 (T\textsubscript{reg} cells)</td>
<td>6 (0.0037)</td>
<td>270 (0.21)</td>
<td>56.76</td>
</tr>
<tr>
<td>Ratio of CD8A\textsuperscript{+} T cells v T\textsubscript{reg} cells</td>
<td>5.83</td>
<td>114.47</td>
<td>19.63</td>
</tr>
<tr>
<td>Ki67+</td>
<td>22,239 (13.82)</td>
<td>7,317 (5.7)</td>
<td>0.41</td>
</tr>
<tr>
<td>CD45RB+/Ki67+</td>
<td>443 (0.28)</td>
<td>4,824 (3.76)</td>
<td>13.43</td>
</tr>
<tr>
<td>CD45RB+/CD3+/Ki67+</td>
<td>217 (0.13)</td>
<td>3,635 (2.83)</td>
<td>21.77</td>
</tr>
<tr>
<td>CD45RB+/CD3+/CD8A+/Ki67+</td>
<td>8 (0.005)</td>
<td>3,116 (2.43)</td>
<td>486</td>
</tr>
<tr>
<td>CD45RB+/CD3+/CD4+/Ki67+</td>
<td>9 (0.0056)</td>
<td>634 (0.49)</td>
<td>87.5</td>
</tr>
<tr>
<td>CD45RB+/CD3+/CD4−/CD8A−/Ki67+</td>
<td>200 (0.12)</td>
<td>328 (0.26)</td>
<td>2.17</td>
</tr>
<tr>
<td>IBA1+/CD14+/Ki67+</td>
<td>4,872 (3.03)</td>
<td>4,135 (3.24)</td>
<td>1.07</td>
</tr>
<tr>
<td>CD45RB−/IBA1−/CD14−/Ki67+</td>
<td>12,968 (8.06)</td>
<td>1,035 (0.81)</td>
<td>1.00</td>
</tr>
</tbody>
</table>

**Table 1.** Immune Profile of the Pre-Nivolumab (Sample 6) and Post-Nivolumab (Sample 7)–Treated Meningioma Samples Using t-CyCIF

Abbreviations: PD-1, programmed cell death 1; PD-L1, programmed cell death 1 ligand; t-CyCIF, tissue-based multiplexed cyclic immunofluorescence; T\textsubscript{reg}, regulatory T cells.
Fig 3. Genomic and immunohistochemical characterization of meningioma samples. (A) Copy number analysis from targeted next-generation sequencing data from sample 6 identified a genome-wide profile characteristic of a high-grade meningioma, including loss of 1p, 9p and monosomy of chromosomes 18 and 22. Focal homozygous deletion of CDKN2A/CDKN2B and intragenic deletion of MSH2 were present. (B) Gene-level view of MSH2 showed a homozygous intragenic deletion of exons 2 through 5 of MSH2 (NM_000251; log2 ratio from −2.21 to −2.73) in the setting of 2p arm-level single copy loss. Copy number is depicted as a log2 ratio value. Immunohistochemistry on pretreatment meningioma resection (surgery 4/sample 4; S4) for (C) MSH2, (D) MSH6, (E) MLH1, and (F) PMS2. MSH2 and MSH6 staining was present only in nontumor cells. (G) Box and whiskers plot (5th to 95th percentiles) of tumor mutational burden (TMB; mutations per megabase) for Brigham and Women's Hospital (BWH)/Dana-Farber Cancer Institute (DFCI) profile initiative cohort (n = 228 sequenced cases; Data Supplement) plus sequencing data for the mismatch repair (MMR)–deficient case BWH/DFCI 2 and for the Foundation Medicine cohort (FMI; n = 615 sequenced cases; Data Supplement). Patient cases with loss of function changes in MMR and MMR-related genes (from Table 2) are highlighted in red (dots and squares). For the BWH/DFCI profile initiative cohort, the mean TMB was 4.25 mutations/megabase (standard deviation, 2.55; standard error of the mean, 0.17; lower 95% CI of mean, 3.91; upper 95% CI of mean, 4.58). For the Foundation Medicine cohort, the mean TMB was 2.77 mutations/megabase (standard deviation, 8.08; standard error of the mean, 0.33; lower 95% CI of mean, 2.14; upper 95% CI of mean, 3.41).
the enlargement of lesions and increased signal abnormalities seen on the MRI after nivolumab reflected pseudoprogression, not tumor growth. In addition to inactivation of \( \text{MSH2} \), sequencing of the patient’s tumors revealed missense mutations in \( \text{POLD1} \) (R639C), \( \text{RAD50} \) (P571L), and \( \text{POLE} \) (G203E, S30L), but these changes are of unclear significance and are predicted to be nonpathogenic. An increase in TMB from 26.6 mutations/MB in sample 4 (before experimental therapies) to 38.0 in sample 6 raises the possibility that temozolomide can augment TMB in meningioma. However, this neoplasm was MMR deficient at the time of original diagnosis; thus, temozolomide did not drive acquired MMR deficiency.

This work also shows that approximately 2.5% of meningiomas have a high mutation burden, a phenotype that has been linked with neoantigen expression in other tumor types. In a subset of mutation-rich meningiomas, loss of function alterations in MMR and MMR-related genes can be detected. It is possible that other, as yet unknown or undetected, mutations contribute to high TMB in the remaining tumors. In all, this first report, to our knowledge, of a dramatic response of an MMR-deficient meningioma to immunotherapy and our characterization of meningioma cohorts from two different institutions indicate that screening meningiomas is warranted to identify a molecularly defined subtype that is likely responsive to immunotherapy.

**AUTHOR CONTRIBUTIONS:**
Conception and design: Ian F. Dunn, Mehdi Touat, Peter K. Sorger, Keith L. Ligon, Sandro Santagata, David A. Reardon
Provision of study material or patients: Ian F. Dunn, Michael B. Sisti, Peter D. Canoll, Keith L. Ligon, Sandro Santagata, David A. Reardon
Administrative support: Eric Severson, Brenda Acevedo
Financial support: Peter K. Sorger, Sandro Santagata
Data analysis and interpretation: Mehdi Touat, Patrick Y. Wen, Renato Umeter, Adrian M. Dubuc, Matthew Dugar, Peter D. Canoll, Eric Severson, Shakti H. Ramkisson, Jia-Ren Lin, Peter K. Sorger, Keith L. Ligon, Sandro Santagata, David A. Reardon
Collection and assembly of data: Ziming Du, Mehdi Touat, Michael B. Sisti, Julia A. Elvin, Shakti H. Ramkisson, Luis Cabrera, Brenda Acevedo, Keith L. Ligon, Sandro Santagata, David A. Reardon

**Table 2. Additional Meningiomas With Mutations in MMR Genes and MMR-Related Genes From the BWH/DFCI Profile Initiative Cohort and the Foundation Medicine Cohort**

<table>
<thead>
<tr>
<th>Patient</th>
<th>WHO Grade</th>
<th>TMB (mutations/megabase)</th>
<th>Gene</th>
<th>Amino Acid Alteration</th>
<th>MMR IHC in Tumor Cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>BWH/DFCI-1</td>
<td>3</td>
<td>18</td>
<td>( \text{MSH2} )</td>
<td>1510+8delT</td>
<td>MSH2/MSH6 retained</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>( \text{SETD2} )</td>
<td>Splice site (VUS)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E1595Sf*15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BWH/DFCI-2</td>
<td>2</td>
<td>10</td>
<td>( \text{MSH6} )</td>
<td>F1088Sf*2</td>
<td>MSH2/MSH6 negative</td>
</tr>
<tr>
<td>FMI-4</td>
<td>3</td>
<td>30</td>
<td>( \text{MSH2} )</td>
<td>Homozygous deletion</td>
<td>NA</td>
</tr>
<tr>
<td>FMI-6</td>
<td>3</td>
<td>28</td>
<td>( \text{MSH6} )</td>
<td>C5596*3</td>
<td>NA</td>
</tr>
<tr>
<td>FMI-7</td>
<td>3</td>
<td>91</td>
<td>( \text{SETD2} )</td>
<td>N346s*77</td>
<td>NA</td>
</tr>
<tr>
<td>FMI-10</td>
<td>2</td>
<td>25</td>
<td>( \text{POLE} )</td>
<td>R762W</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviations: BWH, Brigham and Women’s Hospital; DFCI, Dana-Farber Cancer Institute; fs, frameshift; IHC, immunohistochemistry; MMR, mismatch repair; NA, tissue sections not available for analysis; TMB, tumor mutational burden; VUS, variant of unknown significance.
Ziming Du
No relationship to disclose

Mehdi Touat
Consulting or Advisory Role: Agios, Taiho Pharmaceutical
Travel, Accommodations, Expenses: Merck Sharp & Dohme

Michael B. Sisti
No relationship to disclose

Patrick Y. Wen
Consulting or Advisory Role: AbbVie, Genentech, Roche, Agios, AstraZeneca, Karyopharm Therapeutics, Vivas, Monteris Medical, Aurora Biopharma, Vascular Biogenics, Kadmon, ZioPharm Oncology, GW Pharmaceuticals, Lilly, Immunomic Therapeutics
Speakers’ Bureau: Merck
Research Funding: Agios (Inst), Abbvie (Inst), Angiochem (Inst), Genentech (Inst), Roche (Inst), GlaxoSmithKline (Inst), AstraZeneca (Inst), ImmunoCellular Therapeutics (Inst), Karyopharm Therapeutics (Inst), Merck (Inst), Novartis (Inst), OncoCeutics (Inst), Sanofi (Inst), ARIAD (Inst), Vascular Biogenics (Inst), Lilly
Research Funding: Karyopharm Therapeutics

Jia-Ren Lin
No relationship to disclose

Lais Cabrera
No relationship to disclose

Brenda Acevedo
No relationship to disclose

Peter K. Sorger
Leadership: RareCyte, Merrimack, Applied BioMath
Stock and Other Ownership Interests: RareCyte, Merrimack, Applied BioMath, Glencoe Software
Honoraria: Novartis
Research Funding: Merck (Inst)

Keith L. Ligon
Stock and Other Ownership Interests: Travera
Consulting or Advisory Role: Midatech
Research Funding: Plexxikon (Inst), Amgen (Inst), X4 Pharma (Inst), Tragara (Inst), Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property: Molecular Diagnostics Assay patent

Sandro Santagata
Consulting or Advisory Role: RareCyte

David A. Reardon
Honoraria: AbbVie, Cavion, Genentech, Roche, Merck, Midatech, Momenta Pharmaceuticals, Novartis, Novocure, Regeneron, Stemline Therapeutics, Celldex, Oxicene, Monteris Medical, Bristol-Myers Squibb, Juno Therapeutics, Inovio Pharmaceuticals, Oncorus
Consulting or Advisory Role: Cavion, Genentech, Roche, Merck, Momenta Pharmaceuticals, Novartis, Novocure, Regeneron, Stemline Therapeutics, Bristol-Myers Squibb, Inovio Pharmaceuticals, Juno Therapeutics, Celldex, Oxicene, Monteris Medical, Midatech, Oncorus
Research Funding: Celldex (Inst), Incyte (Inst), Midatech (Inst), Tragara (Inst), Inovio Pharmaceuticals (Inst), Agenus (Inst), EMD Serono (Inst), Acerta Pharma (Inst)

ACKNOWLEDGMENT
We thank George Zanazzi, MD, for assistance with sample procurement, the staff at the Brigham and Women’s Hospital Center for Advanced Molecular Diagnostics for sequencing, Terri Woo for assistance with immunohistochemistry, and members of the Lab for Systems Pharmacology for helpful comments on the manuscript.

Affiliations
Ian F. Dunn, Ziming Du, Patrick Y. Wen, Adrian M. Dubuc, Keith L. Ligon, and Sandro Santagata, Brigham and Women’s Hospital; Ziming Du, Jia-Ren Lin, Peter K. Sorger, and Sandro Santagata, Harvard Medical School; Mehdi Touat, Patrick Y. Wen, Renato Umerton, Matthew Ducar, Lais Cabrera, Brenda Acevedo, Keith L. Ligon, Sandro Santagata, and David A. Reardon, Dana-Farber Cancer Institute, Boston; Julia A. Elvin, Foundation Medicine, Cambridge, MA; Michael B. Sisti and Peter D. Canoll, Columbia University Medical Center, New York City, NY; Eric Severson and Shakti H. Ramkissoon, Foundation Medicine, Morrisville; and Shakti H. Ramkissoon, Wake Forest School of Medicine, Winston-Salem, NC.

Support
Supported by the Ludwig Center at Harvard Medical School (PKS. and S.S.) and by National Cancer Institute Grant No. U54-CA225088 (to PKS. and S.S.).
REFERENCES


ascopubs.org/journal/po JCO™ Precision Oncology  9


**Fig A1.** Tissue-based multiplexed cyclic immunofluorescence (t-CyCIF) characterization of resection tissues before and after nivolumab treatment. (A) A representative field of view of t-CyCIF imaging data of selected biomarkers generated from a single section of pretreatment meningioma (surgery 6/sample 6). (B) A representative field of view of t-CyCIF imaging data of selected biomarkers generated from a single section of the post-treatment meningioma (surgery 7/sample 7). FOXP3, forkhead box P3; PD-1, programmed death 1; PD-L1, programmed death ligand 1.